A multicenter randomized controlled trial to assess the efficacy of cancer green therapy in treatment of stage IIIb/IV non-small cell lung cancer

Sun, Manqiang; Zhou, Tian; Fang, Xueni; Wang, Dan; Pang, Haoyue; Chen, Yu; Hu, Kaiwen

doi:10.1097/md.0000000000021626

Cited by 8 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a number of malignancies, decreasing tumor burden through cytoreductive cryoablation can have positive effect on survival. In particular, studies have demonstrated that cryoablation leads to better survival in patients with metastatic hepatocellular carcinoma ( 22 ), lung cancer ( 23 ), and melanoma ( 24 ), on top of strengthening tumor response to systemic therapy. Several studies have reported synergies between cryoablation and immune response.…”

Section: Discussionmentioning

confidence: 99%

Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib With or Without Cryoablation

Wang

Zhang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

BackgroundPercutaneous cryoablation (PCA) has emerged as an alternative to extirpative management of small renal masses in select patients. In recent years, the use of targeted therapies has become mainstream, while the role of PCA in treating primary tumor is not well established among patients with metastatic renal cell carcinoma (mRCC). We sought to evaluate how mRCC patients react to PCA in combination with sunitinib.MethodsWe retrospectively identified patients with mRCC (primary tumor diameter ≤ 7 cm) treated with sunitinib between 2013 and 2019. These patients were categorized by initial treatment (cryoablation followed by sunitinib versus sunitinib only). Oncological outcomes and rate of adverse events were compared.ResultsOf the 178 patients analyzed, 65 underwent PCA prior to sunitinib. The median overall survival (OS) in the PCA-sunitinib group was 31.7 months (95% CI; 26.1-37.3), better than the sunitinib-only group, which reported a median OS of 19.8 months (95% CI; 17.1-22.4) (p < 0.001). The median progression-free survival (PFS) in patients treated with PCA-sunitinib versus sunitinib alone was 13.8 months (95% CI; 10.0-17.6) versus 7.2 months (95% CI: 6.1-8.3) (p < 0.005). No significant differences in adverse events were observed (p > 0.05).ConclusionsPCA combined with sunitinib is associated with better survival outcomes than sunitinib alone in patients with mRCC. Careful patient selection remains warranted. These results should inform future prospective trials.

show abstract

Section: Discussionmentioning

confidence: 99%

Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib With or Without Cryoablation

Wang

Zhang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…In China, green cancer therapy is a new form of treatment that combines CA with traditional Chinese medicine (TCM). Sun et al reported that this approach improved survival time and quality of life for patients with stage IIIb/IV NSCLC compared with chemotherapy alone, providing a novel treatment strategy for patients with advanced cancer (88). A previous study also reported the efficacy of CA combined with TCM in treating elderly individuals or those with advanced lung cancer (89).…”

Section: Ca In Advanced Lung Cancermentioning

confidence: 99%

Image-guided percutaneous ablation for lung malignancies

Shang

Li²,

Zhang³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Image-guided percutaneous lung ablation has proven to be an alternative and effective strategy in the treatment of lung cancer and other lung malignancies. Radiofrequency ablation, microwave ablation, and cryoablation are widely used ablation modalities in clinical practice that can be performed along or combined with other treatment modalities. In this context, this article will review the application of different ablation strategies in lung malignancies.

show abstract

“…A new freeze-thawing model was used during lung tumor cryoablation: 5 min freezing, 3 min thawing, 10 min freezing, 3 min thawing, 10 min freezing. This new model is used to generate interstitial fluid in adjacent lung tissue, which further forms a ball of ice into the lung, thereby increasing the ablation range of lung tumors ( 27 ).…”

Section: Cryoablation In the Treatment Of Lung Cancermentioning

confidence: 99%

Cryoablation and immune synergistic effect for lung cancer: A review

Tian

Jiang

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

The preferred treatment for lung cancer is surgical resection, but a large number of patients are not suitable for surgical resection in clinic. CT-guided cryoablation and immunotherapy can play an important role in patients with advanced lung cancer who are ineligible for surgery. CT-guided cryoablation has been widely used in the clinical treatment of lung tumors due to its advantages of less trauma, fewer complications, significant efficacy and rapid recovery. Cryoablation can not only cause tumor necrosis and apoptosis, but also promote the release of tumor-derived autoantigens into the blood circulation, and stimulate the host immune system to produce a good anti-tumor immune effect against primary and metastatic tumors. Since the study of immune checkpoint inhibitors has proved that lung cancer can be an immunotherapeutic response disease, the relationship between cryoablation and immunotherapy of lung cancer has been paid more attention. Therefore, we reviewed the literature on cryoablation for lung cancer, as well as the research progress of cryoablation combined with immunotherapy.

show abstract

A multicenter randomized controlled trial to assess the efficacy of cancer green therapy in treatment of stage IIIb/IV non-small cell lung cancer

Cited by 8 publications

References 20 publications

Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib With or Without Cryoablation

Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib With or Without Cryoablation

Image-guided percutaneous ablation for lung malignancies

Cryoablation and immune synergistic effect for lung cancer: A review

Contact Info

Product

Resources

About